Kochar B, Pate V, Kappelman MD, Long MD, et al. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. Clin Gastroenterol Hepatol 2022;20:1299-1305.
PMID: 34481954